摘要
特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种病因未明的间质性肺疾病,其自然病程呈缓慢渐进性,少部分患者经历一次或几次急性加重,可发展为呼吸衰竭或死亡。肺移植作为IPF患者的治疗方式,仍存在供应有限、感染和免疫排斥等问题。而IPF传统药物治疗疗效欠佳。近年来对IPF致病机制进行了深入研究,使针对新靶点的治疗药物和治疗方案的研制有了新的研究进展。
Idiopathic pulmonary fibrosis(IPF)is a chronic,fatal and idiopathic interstitial pneumonia of unknown etiology,characterised by irreversible lung function decline. The natural course of IPF,while variable over time,is universally progressive,which leads to respiratory insufficiency and death. Lung transplantation remains one of the few effective treatment options of IPF,while there are still some shortcomings such as limited supply acceptable organs,infection and chronic rejection. The curative effect of traditional drugs in the treatment of IPF is insufficient. In recent years,with the in-depth study of the pathogenesis of IPF,several new targeted drugs have been reported.
出处
《沈阳医学院学报》
2018年第1期75-79,共5页
Journal of Shenyang Medical College
关键词
特发性肺纤维化
慢性炎症
药物
idiopathic pulmonary fibrosis
chronic inflammation
medicine
